secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001641172-25-022354
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix reports Q2 2025 net loss $1.5M; merger with Cullgen expected 2025; plans divestment of iSPERSE assets
--------------------------------------------------------------------------------

- Revenue fell to $0 from $1.6M in Q2 2024 due to PUR1900 wind-down; net loss $1.549M ($0.42 per share).
- Cash and equivalents $5.825M; company expects funds to last through expected close of proposed Cullgen merger.
- Proposed merger with Cullgen approved by stockholders; closing in 2025 subject to Nasdaq and China regulatory approvals.
- Pulmatrix intends to divest iSPERSE technology and clinical programs PUR3100, PUR1800, PUR1900 as part of merger.
- R&D expenses dropped to $0.1M from $2.8M; G&A decreased to $1.5M from $2.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000164117225022354/0001641172-25-022354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000164117225022354/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer